A Phase 3 interventional study of V116 and PPSV23 in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 72 sites in 8 countries. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-24.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 3rd largest by enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 4th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2022.
This study's enrollment of 2,162 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 4th largest by enrollment, is one of 5 that started in 2022, is one of 31 in phase 3, and was the 38th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in pneumococcal vaccine-naïve adults 18 to 49 years of age.
The primary study hypothesis is that all 3 lots of V116 are equivalent as assessed by the serotype-specific opsonophagocytic activity (OPA) Geometric Mean Titers (GMTs) at 30 days postvaccination for all serotypes included in V116.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single 0.5 mL intramuscular (IM) dose of V116 Lot 1 on Day 1.
Biological: V116
Participants will receive a single 0.5 mL IM dose of V116 Lot 2 on Day 1.
Biological: V116
Participants will receive a single 0.5 mL IM dose of V116 Lot 3 on Day 1.
Biological: V116
Participants will receive a single 0.5 mL IM dose of PPSV23 on Day 1.
Biological: PPSV23
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Also known as: Pneumococcal 21-valent Conjugate Vaccine
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Also known as: PNEUMOVAX™23
Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 Lots
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Up to 5 days
Percentage of Participants With Solicited Injection-site AEs Following Vaccination: Combined Lots of V116 or PPSV23
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.
Time frame: Up to 5 days
Percentage of Participants With Solicited Systemic AEs Following Vaccination With Separate V116 Lots
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Up to 5 days
Percentage of Participants With Solicited Systemic AEs Following Vaccination: Combined Lots of V116 or PPSV23
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.
Time frame: Up to 5 days
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 Lots
An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Up to 194 days
Percentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV23
An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per the statistical analysis plan, no within group MOD were planned or calculated.
Time frame: Up to 194 days
Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Day 30
GMTs of Serotype-specific OPA for All Serotypes in V116 Following Vaccination: Combined Lots of V116 or PPSV23
Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CI were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.
Time frame: Day 30
Geometric Mean Concentrations (GMCs) of Serotype-specific Immunoglobulin G (IgG) for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Serotype-specific IgG concentrations for all serotypes in V116 following vaccination were determined using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Day 30
GMCs of Serotype-specific IgG for All Serotypes in V116 Following Vaccination: Combined Lots of V116 or PPSV23
Serotype-specific IgG concentrations for all serotypes in V116 following vaccination were determined using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
Time frame: Day 30
Geometric Mean Fold Rise (GMFR) in Serotype-specific OPA for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Serotype-specific OPA GMFR for all serotypes in V116 following vaccination were determined using MOPA. The GMFR of each pneumococcal serotype was calculated as Day 30 GMT/Day 1 GMT. The 95% CIs were calculated based on based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Baseline (Day 1) and Day 30
Percentage of Participants With ≥4-fold Rise in Serotype-specific OPA for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Serotype-specific OPA titer were determined using MOPA. The percentage of participants with a ≥4-fold rise in serotype-specific OPA for all serotypes in V116 following vaccination were reported. The 95% CIs were calculated based on the exact binomial method proposed by Clopper and Pearson. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Baseline (Day 1) and Day 30
GMFR in Serotype-specific IgG for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Serotype-specific IgG GMFR for all serotypes in V116 following vaccination were determined using PnECL. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMC/Day 1 GMC. The 95% CIs were calculated based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Baseline (Day 1) and Day 30
Percentage of Participants With ≥4-fold Rise in Serotype-specific IgG for All Serotypes in V116 Following Vaccination With Separate V116 Lots
Serotype-specific IgG concentrations were determined using PnECL. The percentage of participants with a ≥4-fold rise in serotype-specific IgG for all serotypes in V116 were reported. The 95% CIs were calculated based on the exact binomial method proposed by Clopper and Pearson. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Baseline (Day 1) and Day 30
GMTs of Serotype-specific OPA for Cross-reactive Serotypes Following Vaccination With Separate V116 Lots
Serotype-specific OPA titers for cross-reactive serotypes (6A, 6C, 15B, and 15C) were determined using MOPA. The 95% CIs for serotype-specific OPA GMTs were calculated based on based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
Time frame: Day 30
Healthy pneumococcal vaccine-naïve adults between 18 and 49 years of age were enrolled in this study.
| Milestone | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Started | 541 | 540 | 541 | 540 |
| Vaccinated | 539 | 538 | 540 | 540 |
| Safety analysis population | 539 | 536 | 541 | 541 |
| Completed | 521 | 520 | 525 | 526 |
| Not completed | 20 | 20 | 16 | 14 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 16 | 11 | 11 | 11 |
| Withdrew: Randomized in error without study treatment | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 8 | 3 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Unable to adhere to study schedule | 0 | 0 | 1 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Percentage of Participants | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Injection site erythema | 13.4 (10.6 to 16.5) | 14.2 (11.3 to 17.4) | 13.1 (10.4 to 16.3) | — |
| Injection site pain | 72.9 (68.9 to 76.6) | 72.9 (69.0 to 76.7) | 73.9 (70.0 to 77.6) | — |
| Injection site swelling | 12.4 (9.8 to 15.5) | 15.3 (12.4 to 18.6) | 11.8 (9.2 to 14.9) | — |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited injection-site AEs included pain/tenderness, redness/erythema, and swelling. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.
| Percentage of Participants | V116 Combined Lots 1, 2, and 3 | PPSV23 |
|---|---|---|
| Injection site erythema | 13.6 | 7.6 |
| Injection site pain | 73.3 | 60.6 |
| Injection site swelling | 13.2 | 7.6 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Percentage of Participants | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Fatigue | 38.0 (33.9 to 42.3) | 34.0 (30.0 to 38.1) | 34.4 (30.4 to 38.6) | — |
| Headache | 28.0 (24.3 to 32.0) | 26.1 (22.4 to 30.1) | 27.5 (23.8 to 31.5) | — |
| Myalgia | 18.2 (15.0 to 21.7) | 13.6 (10.8 to 16.8) | 17.2 (14.1 to 20.6) | — |
| Pyrexia | 3.2 (1.8 to 5.0) | 2.2 (1.2 to 3.9) | 3.5 (2.1 to 5.4) | — |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Solicited systemic AEs included headache, muscle aches/myalgia, tiredness/fatigue, and pyrexia. Per the statistical analysis plan, no within group method of dispersion (MOD) were planned or calculated.
| Percentage of Participants | V116 Combined Lots 1, 2, and 3 | PPSV23 |
|---|---|---|
| Fatigue | 35.5 | 34.0 |
| Headache | 27.2 | 21.4 |
| Myalgia | 16.3 | 8.7 |
| Pyrexia | 3.0 | 2.2 |
An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Percentage of Participants | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 Lots | 0.0 (0.0 to 0.7) | 0.0 (0.0 to 0.7) | 0.0 (0.0 to 0.7) | — |
An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. SAEs that were reported to be at least possibly related by the investigator to study vaccination were reported. Per the statistical analysis plan, no within group MOD were planned or calculated.
| Percentage of Participants | V116 Combined Lots 1, 2, and 3 | PPSV23 |
|---|---|---|
| Percentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV23 | 0.0 | 0.0 |
Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using multiplex opsonophagocytic assay (MOPA). Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Titers | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Serotype 3 | 327.2 (NA to NA) | 299.0 (NA to NA) | 318.8 (NA to NA) | — |
| Serotype 6A | 6901.9 (NA to NA) | 6014.9 (NA to NA) | 6641.2 (NA to NA) | — |
| Serotype 7F | 7219.8 (NA to NA) | 6201.8 (NA to NA) | 6657.0 (NA to NA) | — |
| Serotype 8 | 3935.5 (NA to NA) | 3812.8 (NA to NA) | 3765.8 (NA to NA) | — |
| Serotype 9N | 18747.4 (NA to NA) | 17201.6 (NA to NA) | 18557.8 (NA to NA) | — |
| Serotype 10A | 7570.2 (NA to NA) | 7796.9 (NA to NA) | 7330.4 (NA to NA) | — |
| Serotype 11A | 6396.0 (NA to NA) | 6630.9 (NA to NA) | 6374.5 (NA to NA) | — |
| Serotype 12F | 7478.5 (NA to NA) | 6803.0 (NA to NA) | 7329.9 (NA to NA) | — |
| Serotype 15A | 10698.5 (NA to NA) | 10253.9 (NA to NA) | 10692.3 (NA to NA) | — |
| Serotype 15C | 13133.8 (NA to NA) | 11441.3 (NA to NA) | 11177.1 (NA to NA) | — |
| Serotype 16F | 9239.1 (NA to NA) | 9550.8 (NA to NA) | 9530.1 (NA to NA) | — |
| Serotype 17F | 17185.3 (NA to NA) | 17718.6 (NA to NA) | 16886.7 (NA to NA) | — |
| Serotype 19A | 3187.1 (NA to NA) | 3123.3 (NA to NA) | 3368.0 (NA to NA) | — |
| Serotype 20A | 16339.3 (NA to NA) | 16676.2 (NA to NA) | 15302.4 (NA to NA) | — |
| Serotype 22F | 11638.5 (NA to NA) | 10614.3 (NA to NA) | 11346.7 (NA to NA) | — |
| Serotype 23A | 8437.4 (NA to NA) | 8459.8 (NA to NA) | 8322.8 (NA to NA) | — |
| Serotype 23B | 2964.1 (NA to NA) | 2435.5 (NA to NA) | 3035.5 (NA to NA) | — |
| Serotype 24F | 4861.3 (NA to NA) | 4783.4 (NA to NA) | 4758.8 (NA to NA) | — |
| Serotype 31 | 9052.0 (NA to NA) | 8831.6 (NA to NA) | 8870.7 (NA to NA) | — |
| Serotype 33F | 37994.1 (NA to NA) | 34227.3 (NA to NA) | 35182.5 (NA to NA) | — |
| Serotype 35B | 12971.8 (NA to NA) | 12586.6 (NA to NA) | 12494.5 (NA to NA) | — |
Serotype-specific OPA titers for all serotypes in V116 following vaccination were determined using MOPA. Serotype-specific OPA GMTs and GMT ratios with 95% CI were calculated using a constrained longitudinal data analysis (cLDA) model. Per protocol, within-group CIs were not calculated.
| Titers | V116 Combined Lots 1, 2 and 3 | PPSV23 |
|---|---|---|
| Serotype 3 | 316.5 (NA to NA) | 339.8 (NA to NA) |
| Serotype 6A | 6491.7 (NA to NA) | 1866.4 (NA to NA) |
| Serotype 7F | 6702.2 (NA to NA) | 5058.1 (NA to NA) |
| Serotype 8 | 3847.3 (NA to NA) | 4543.3 (NA to NA) |
| Serotype 9N | 18166.7 (NA to NA) | 19031.9 (NA to NA) |
| Serotype 10A | 7618.2 (NA to NA) | 5763.0 (NA to NA) |
| Serotype 11A | 6494.4 (NA to NA) | 3728.0 (NA to NA) |
| Serotype 12F | 7196.9 (NA to NA) | 5207.5 (NA to NA) |
| Serotype 15A | 10520.0 (NA to NA) | 2608.5 (NA to NA) |
| Serotype 15C | 11922.3 (NA to NA) | 4112.0 (NA to NA) |
| Serotype 16F | 9415.3 (NA to NA) | 2532.2 (NA to NA) |
| Serotype 17F | 17330.5 (NA to NA) | 10159.9 (NA to NA) |
| Serotype 19A | 3222.9 (NA to NA) | 3474.7 (NA to NA) |
| Serotype 20A | 16183.8 (NA to NA) | 10994.2 (NA to NA) |
| Serotype 22F | 11118.1 (NA to NA) | 8308.0 (NA to NA) |
| Serotype 23A | 8428.3 (NA to NA) | 1056.1 (NA to NA) |
| Serotype 23B | 2825.4 (NA to NA) | 119.1 (NA to NA) |
| Serotype 24F | 4892.9 (NA to NA) | 250.3 (NA to NA) |
| Serotype 31 | 8865.6 (NA to NA) | 654.5 (NA to NA) |
| Serotype 33F | 35684.3 (NA to NA) | 42515.6 (NA to NA) |
| Serotype 35B | 12798.6 (NA to NA) | 3452.1 (NA to NA) |
Serotype-specific IgG concentrations for all serotypes in V116 following vaccination were determined using pneumococcal electrochemiluminescence (PnECL). Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated and the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| μg/mL | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Serotype 3 | 0.83 (NA to NA) | 0.85 (NA to NA) | 0.87 (NA to NA) | — |
| Serotype 6A | 5.94 (NA to NA) | 5.29 (NA to NA) | 5.84 (NA to NA) | — |
| Serotype 7F | 5.13 (NA to NA) | 5.29 (NA to NA) | 4.99 (NA to NA) | — |
| Serotype 8 | 10.32 (NA to NA) | 10.52 (NA to NA) | 10.42 (NA to NA) | — |
| Serotype 9N | 5.37 (NA to NA) | 5.11 (NA to NA) | 6.03 (NA to NA) | — |
| Serotype 10A | 9.63 (NA to NA) | 9.52 (NA to NA) | 9.97 (NA to NA) | — |
| Serotype 11A | 6.33 (NA to NA) | 6.28 (NA to NA) | 6.21 (NA to NA) | — |
| Serotype 12F | 1.65 (NA to NA) | 1.75 (NA to NA) | 1.65 (NA to NA) | — |
| Serotype 15A | 13.63 (NA to NA) | 13.00 (NA to NA) | 14.20 (NA to NA) | — |
| Serotype 15C | 14.32 (NA to NA) | 13.54 (NA to NA) | 13.85 (NA to NA) | — |
| Serotype 16F | 1.77 (NA to NA) | 1.97 (NA to NA) | 1.96 (NA to NA) | — |
| Serotype 17F | 14.05 (NA to NA) | 13.37 (NA to NA) | 13.14 (NA to NA) | — |
| Serotype 19A | 7.70 (NA to NA) | 7.94 (NA to NA) | 8.51 (NA to NA) | — |
| Serotype 20A | 13.54 (NA to NA) | 14.18 (NA to NA) | 14.09 (NA to NA) | — |
| Serotype 22F | 7.02 (NA to NA) | 6.97 (NA to NA) | 6.99 (NA to NA) | — |
| Serotype 23A | 4.26 (NA to NA) | 4.34 (NA to NA) | 4.34 (NA to NA) | — |
| Serotype 23B | 6.77 (NA to NA) | 6.65 (NA to NA) | 7.39 (NA to NA) | — |
| Serotype 24F | 4.32 (NA to NA) | 4.55 (NA to NA) | 4.34 (NA to NA) | — |
| Serotype 31 | 3.47 (NA to NA) | 3.94 (NA to NA) | 3.47 (NA to NA) | — |
| Serotype 33F | 8.03 (NA to NA) | 7.94 (NA to NA) | 8.00 (NA to NA) | — |
| Serotype 35B | 11.84 (NA to NA) | 11.56 (NA to NA) | 11.94 (NA to NA) | — |
Serotype-specific IgG concentrations for all serotypes in V116 following vaccination were determined using PnECL. Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% confidence intervals were calculated using a cLDA model. Per protocol, within-group CIs were not calculated.
| μg/mL | V116 Combined Lots 1, 2, and 3 | PPSV23 |
|---|---|---|
| Serotype 3 | 0.85 (NA to NA) | 0.77 (NA to NA) |
| Serotype 6A | 5.67 (NA to NA) | 1.45 (NA to NA) |
| Serotype 7F | 5.19 (NA to NA) | 3.36 (NA to NA) |
| Serotype 8 | 10.34 (NA to NA) | 12.85 (NA to NA) |
| Serotype 9N | 5.51 (NA to NA) | 5.41 (NA to NA) |
| Serotype 10A | 9.58 (NA to NA) | 6.52 (NA to NA) |
| Serotype 11A | 6.29 (NA to NA) | 4.55 (NA to NA) |
| Serotype 12F | 1.69 (NA to NA) | 1.20 (NA to NA) |
| Serotype 15A | 13.55 (NA to NA) | 1.99 (NA to NA) |
| Serotype 15C | 13.90 (NA to NA) | 4.29 (NA to NA) |
| Serotype 16F | 1.91 (NA to NA) | 0.30 (NA to NA) |
| Serotype 17F | 13.46 (NA to NA) | 7.28 (NA to NA) |
| Serotype 19A | 8.01 (NA to NA) | 7.29 (NA to NA) |
| Serotype 20A | 13.82 (NA to NA) | 9.03 (NA to NA) |
| Serotype 22F | 7.04 (NA to NA) | 5.34 (NA to NA) |
| Serotype 23A | 4.29 (NA to NA) | 0.53 (NA to NA) |
| Serotype 23B | 6.96 (NA to NA) | 1.21 (NA to NA) |
| Serotype 24F | 4.44 (NA to NA) | 0.31 (NA to NA) |
| Serotype 31 | 3.62 (NA to NA) | 0.38 (NA to NA) |
| Serotype 33F | 8.00 (NA to NA) | 9.82 (NA to NA) |
| Serotype 35B | 11.71 (NA to NA) | 1.66 (NA to NA) |
Serotype-specific OPA GMFR for all serotypes in V116 following vaccination were determined using MOPA. The GMFR of each pneumococcal serotype was calculated as Day 30 GMT/Day 1 GMT. The 95% CIs were calculated based on based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Ratio | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Serotype 3 | 8.2 (7.2 to 9.4) | 8.1 (7.2 to 9.1) | 8.2 (7.3 to 9.3) | — |
| Serotype 6A | 46.8 (38.5 to 56.8) | 37.8 (31.1 to 45.9) | 35.8 (29.7 to 43.2) | — |
| Serotype 7F | 17.6 (14.6 to 21.2) | 14.2 (11.8 to 17.0) | 14.8 (12.4 to 17.6) | — |
| Serotype 8 | 17.6 (14.7 to 21.1) | 16.2 (13.6 to 19.2) | 15.4 (12.9 to 18.5) | — |
| Serotype 9N | 10.1 (8.8 to 11.7) | 10.4 (9.0 to 12.0) | 10.5 (9.0 to 12.2) | — |
| Serotype 10A | 14.1 (11.8 to 16.7) | 15.2 (12.8 to 18.0) | 15.9 (13.3 to 18.9) | — |
| Serotype 11A | 11.5 (9.5 to 14.0) | 11.3 (9.3 to 13.8) | 9.3 (7.8 to 11.1) | — |
| Serotype 12F | 173.7 (144.8 to 208.5) | 152.0 (127.5 to 181.2) | 194.1 (162.5 to 231.7) | — |
| Serotype 15A | 9.3 (7.8 to 11.2) | 8.8 (7.5 to 10.5) | 9.5 (7.9 to 11.3) | — |
| Serotype 15C | 86.0 (68.7 to 107.8) | 78.8 (64.0 to 97.0) | 63.8 (51.2 to 79.5) | — |
| Serotype 16F | 7.1 (6.2 to 8.2) | 7.6 (6.6 to 8.8) | 6.9 (6.2 to 7.8) | — |
| Serotype 17F | 17.8 (15.3 to 20.9) | 18.5 (15.8 to 21.6) | 16.9 (14.4 to 19.8) | — |
| Serotype 19A | 8.9 (7.7 to 10.3) | 8.5 (7.4 to 9.9) | 8.9 (7.8 to 10.3) | — |
| Serotype 20A | 10.6 (9.1 to 12.3) | 11.7 (10.2 to 13.4) | 9.5 (8.3 to 10.8) | — |
| Serotype 22F | 20.0 (16.1 to 24.7) | 15.4 (12.6 to 18.8) | 18.1 (14.9 to 22.0) | — |
| Serotype 23A | 30.9 (24.8 to 38.4) | 27.7 (22.6 to 34.1) | 30.0 (24.5 to 36.7) | — |
| Serotype 23B | 104.1 (85.2 to 127.2) | 91.0 (74.5 to 111.2) | 106.0 (87.2 to 128.8) | — |
| Serotype 24F | 27.0 (22.2 to 32.9) | 24.0 (19.6 to 29.2) | 25.4 (20.8 to 31.0) | — |
| Serotype 31 | 25.1 (20.3 to 31.2) | 25.7 (20.9 to 31.6) | 21.2 (17.2 to 26.1) | — |
| Serotype 33F | 13.1 (11.2 to 15.2) | 12.5 (10.7 to 14.5) | 12.3 (10.6 to 14.2) | — |
| Serotype 35B | 4.6 (4.1 to 5.2) | 5.0 (4.4 to 5.7) | 4.7 (4.1 to 5.3) | — |
Serotype-specific OPA titer were determined using MOPA. The percentage of participants with a ≥4-fold rise in serotype-specific OPA for all serotypes in V116 following vaccination were reported. The 95% CIs were calculated based on the exact binomial method proposed by Clopper and Pearson. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Percentage of Participants | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Serotype 3 | 70.7 (66.1 to 75.1) | 71.0 (66.4 to 75.2) | 70.6 (66.1 to 74.9) | — |
| Serotype 6A | 87.2 (83.3 to 90.4) | 86.5 (82.7 to 89.7) | 85.6 (81.8 to 88.9) | — |
| Serotype 7F | 73.5 (69.1 to 77.6) | 69.7 (65.1 to 73.9) | 71.7 (67.2 to 75.9) | — |
| Serotype 8 | 72.7 (68.3 to 76.7) | 75.9 (71.7 to 79.7) | 70.4 (66.0 to 74.5) | — |
| Serotype 9N | 69.6 (65.1 to 73.9) | 70.4 (65.9 to 74.6) | 72.1 (67.6 to 76.3) | — |
| Serotype 10A | 70.6 (66.1 to 74.9) | 75.1 (70.8 to 79.0) | 73.8 (69.5 to 77.8) | — |
| Serotype 11A | 64.3 (59.5 to 68.8) | 66.0 (61.3 to 70.4) | 61.3 (56.7 to 65.9) | — |
| Serotype 12F | 94.5 (91.9 to 96.4) | 94.5 (92.0 to 96.4) | 95.6 (93.2 to 97.3) | — |
| Serotype 15A | 66.9 (61.3 to 72.1) | 66.2 (60.7 to 71.3) | 67.5 (62.1 to 72.6) | — |
| Serotype 15C | 87.5 (83.8 to 90.6) | 90.3 (87.0 to 93.0) | 88.3 (84.7 to 91.3) | — |
| Serotype 16F | 66.0 (61.0 to 70.7) | 63.7 (58.8 to 68.4) | 62.5 (57.6 to 67.3) | — |
| Serotype 17F | 82.0 (78.1 to 85.5) | 81.4 (77.5 to 84.9) | 80.8 (76.9 to 84.3) | — |
| Serotype 19A | 65.2 (60.6 to 69.7) | 65.0 (60.4 to 69.3) | 66.2 (61.8 to 70.5) | — |
| Serotype 20A | 72.3 (67.5 to 76.8) | 77.8 (73.4 to 81.8) | 72.7 (68.1 to 77.0) | — |
| Serotype 22F | 76.3 (71.9 to 80.3) | 73.3 (68.7 to 77.5) | 78.4 (74.2 to 82.3) | — |
| Serotype 23A | 79.7 (75.0 to 83.8) | 79.4 (74.9 to 83.4) | 82.1 (77.7 to 85.9) | — |
| Serotype 23B | 91.4 (88.3 to 93.8) | 89.3 (86.0 to 92.0) | 90.3 (87.2 to 92.9) | — |
| Serotype 24F | 78.9 (74.4 to 82.8) | 78.2 (73.8 to 82.2) | 76.7 (72.2 to 80.7) | — |
| Serotype 31 | 78.3 (73.9 to 82.4) | 79.1 (74.8 to 82.9) | 77.6 (73.2 to 81.6) | — |
| Serotype 33F | 75.3 (70.7 to 79.5) | 73.2 (68.7 to 77.5) | 75.1 (70.7 to 79.1) | — |
| Serotype 35B | 52.9 (48.0 to 57.7) | 49.5 (44.7 to 54.3) | 48.5 (43.8 to 53.3) | — |
Serotype-specific IgG GMFR for all serotypes in V116 following vaccination were determined using PnECL. The GMFR for each pneumococcal IgG serotype was calculated as Day 30 GMC/Day 1 GMC. The 95% CIs were calculated based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Ratio | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Serotype 3 | 4.4 (4.0 to 4.8) | 4.7 (4.3 to 5.2) | 4.6 (4.1 to 5.0) | — |
| Serotype 6A | 21.2 (18.7 to 24.1) | 18.8 (16.6 to 21.5) | 21.0 (18.7 to 23.7) | — |
| Serotype 7F | 13.7 (12.3 to 15.2) | 13.4 (12.1 to 14.8) | 12.6 (11.3 to 14.0) | — |
| Serotype 8 | 14.3 (12.7 to 16.2) | 15.2 (13.5 to 17.0) | 14.5 (12.8 to 16.4) | — |
| Serotype 9N | 15.9 (14.3 to 17.8) | 15.3 (13.6 to 17.3) | 17.1 (15.2 to 19.3) | — |
| Serotype 10A | 15.0 (13.4 to 16.8) | 15.2 (13.5 to 17.1) | 15.7 (14.0 to 17.6) | — |
| Serotype 11A | 7.2 (6.5 to 8.0) | 7.2 (6.5 to 8.0) | 7.0 (6.3 to 7.8) | — |
| Serotype 12F | 16.3 (14.4 to 18.4) | 17.1 (15.1 to 19.3) | 15.8 (14.1 to 17.8) | — |
| Serotype 15A | 23.1 (20.6 to 25.9) | 22.8 (20.4 to 25.5) | 23.4 (20.9 to 26.3) | — |
| Serotype 15C | 28.5 (25.3 to 32.2) | 27.8 (24.7 to 31.3) | 27.3 (24.2 to 30.9) | — |
| Serotype 16F | 8.4 (7.6 to 9.3) | 8.8 (7.9 to 9.9) | 9.1 (8.2 to 10.1) | — |
| Serotype 17F | 23.5 (21.0 to 26.3) | 23.1 (20.6 to 25.9) | 21.5 (19.2 to 24.1) | — |
| Serotype 19A | 5.5 (4.9 to 6.1) | 5.8 (5.2 to 6.4) | 6.0 (5.4 to 6.7) | — |
| Serotype 20A | 9.2 (8.3 to 10.3) | 9.8 (8.8 to 10.9) | 9.8 (8.8 to 10.9) | — |
| Serotype 22F | 20.4 (17.9 to 23.3) | 19.1 (16.6 to 22.0) | 19.4 (17.0 to 22.2) | — |
| Serotype 23A | 20.3 (18.0 to 22.8) | 20.1 (17.9 to 22.5) | 20.3 (18.0 to 22.9) | — |
| Serotype 23B | 13.9 (12.2 to 15.7) | 14.0 (12.2 to 16.0) | 15.0 (13.2 to 17.1) | — |
| Serotype 24F | 14.7 (13.0 to 16.6) | 15.4 (13.6 to 17.5) | 14.6 (12.9 to 16.6) | — |
| Serotype 31 | 13.6 (12.3 to 15.0) | 15.7 (14.1 to 17.5) | 13.0 (11.7 to 14.5) | — |
| Serotype 33F | 8.8 (7.9 to 9.8) | 9.1 (8.2 to 10.1) | 9.1 (8.2 to 10.0) | — |
| Serotype 35B | 7.3 (6.5 to 8.1) | 7.3 (6.6 to 8.1) | 7.2 (6.5 to 8.0) | — |
Serotype-specific IgG concentrations were determined using PnECL. The percentage of participants with a ≥4-fold rise in serotype-specific IgG for all serotypes in V116 were reported. The 95% CIs were calculated based on the exact binomial method proposed by Clopper and Pearson. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Percentage of Participants | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Serotype 3 | 51.8 (47.3 to 56.3) | 54.4 (49.9 to 58.8) | 52.0 (47.5 to 56.4) | — |
| Serotype 6A | 87.8 (84.6 to 90.6) | 85.3 (81.9 to 88.2) | 89.3 (86.3 to 91.9) | — |
| Serotype 7F | 83.2 (79.6 to 86.4) | 84.1 (80.6 to 87.2) | 82.6 (79.0 to 85.8) | — |
| Serotype 8 | 80.5 (76.8 to 83.9) | 82.7 (79.1 to 85.9) | 81.4 (77.8 to 84.7) | — |
| Serotype 9N | 86.0 (82.6 to 88.9) | 84.1 (80.6 to 87.2) | 82.8 (79.2 to 86.0) | — |
| Serotype 10A | 82.8 (79.2 to 86.0) | 82.4 (78.8 to 85.7) | 83.4 (79.9 to 86.5) | — |
| Serotype 11A | 67.4 (63.1 to 71.5) | 67.3 (63.0 to 71.4) | 63.8 (59.5 to 68.0) | — |
| Serotype 12F | 83.8 (80.3 to 86.9) | 85.1 (81.6 to 88.1) | 84.4 (80.9 to 87.4) | — |
| Serotype 15A | 91.1 (88.2 to 93.4) | 89.2 (86.2 to 91.8) | 90.3 (87.4 to 92.7) | — |
| Serotype 15C | 90.9 (88.0 to 93.3) | 90.8 (88.0 to 93.2) | 90.1 (87.2 to 92.6) | — |
| Serotype 16F | 73.2 (69.1 to 77.1) | 72.5 (68.4 to 76.4) | 74.7 (70.6 to 78.4) | — |
| Serotype 17F | 90.3 (87.3 to 92.7) | 91.0 (88.2 to 93.4) | 87.7 (84.6 to 90.5) | — |
| Serotype 19A | 58.5 (54.0 to 62.9) | 58.6 (54.1 to 62.9) | 59.3 (54.9 to 63.6) | — |
| Serotype 20A | 72.9 (68.7 to 76.7) | 76.1 (72.1 to 79.8) | 74.8 (70.8 to 78.5) | — |
| Serotype 22F | 84.2 (80.7 to 87.3) | 79.5 (75.7 to 82.9) | 84.2 (80.7 to 87.3) | — |
| Serotype 23A | 89.0 (85.9 to 91.6) | 88.8 (85.8 to 91.5) | 86.3 (83.0 to 89.2) | — |
| Serotype 23B | 77.6 (73.7 to 81.2) | 77.1 (73.2 to 80.7) | 78.6 (74.8 to 82.1) | — |
| Serotype 24F | 81.1 (77.4 to 84.5) | 80.9 (77.2 to 84.2) | 79.6 (75.9 to 83.1) | — |
| Serotype 31 | 85.8 (82.4 to 88.7) | 84.3 (80.8 to 87.3) | 82.4 (78.8 to 85.6) | — |
| Serotype 33F | 73.5 (69.4 to 77.3) | 71.7 (67.6 to 75.6) | 73.7 (69.6 to 77.5) | — |
| Serotype 35B | 67.8 (63.5 to 71.9) | 66.7 (62.4 to 70.8) | 64.2 (59.8 to 68.3) | — |
Serotype-specific OPA titers for cross-reactive serotypes (6A, 6C, 15B, and 15C) were determined using MOPA. The 95% CIs for serotype-specific OPA GMTs were calculated based on based on the t-distribution. Per protocol, the PPSV23 treatment group was not included as it was not analyzed with the individual lots of V116.
| Titers | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Serotype 6A | 6849.6 (6120.8 to 7665.0) | 6009.2 (5348.8 to 6751.0) | 6724.3 (5967.6 to 7577.0) | — |
| Serotype 6C | 3972.7 (3501.8 to 4506.9) | 3421.5 (3006.5 to 3893.8) | 3750.9 (3298.0 to 4265.9) | — |
| Serotype 15B | 11799.5 (10317.9 to 13493.8) | 10062.4 (8838.3 to 11456.1) | 11139.5 (9619.7 to 12899.4) | — |
| Serotype 15C | 13079.8 (11543.5 to 14820.6) | 11332.5 (9905.9 to 12964.7) | 11290.9 (9805.6 to 13001.2) | — |
Collected over Non-serious adverse events were collected up to 30 days postvaccination. Serious adverse events and all-cause mortality were reported throughout the duration of the study, up to 194 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V116 Lot 1 | 0/541 (0%) | 8/539 (1.5%) | 428/539 (79.4%) |
| V116 Lot 2 | 0/540 (0%) | 5/536 (0.9%) | 415/536 (77.4%) |
| V116 Lot 3 | 0/541 (0%) | 1/541 (0.2%) | 421/541 (77.8%) |
| PPSV23 | 1/540 (0.2%) | 6/541 (1.1%) | 388/541 (71.7%) |
| Event | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Chest discomfortGeneral disorders | 0/539 | 1/536 | 0/541 | 0/541 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/539 | 1/536 | 0/541 | 0/541 |
| Bipolar disorderPsychiatric disorders | 0/539 | 1/536 | 1/541 | 0/541 |
| DepressionPsychiatric disorders | 0/539 | 1/536 | 0/541 | 0/541 |
| Major depressionPsychiatric disorders | 0/539 | 1/536 | 0/541 | 0/541 |
| Intestinal perforationGastrointestinal disorders | 1/539 | 0/536 | 0/541 | 0/541 |
| Abdominal abscessInfections and infestations | 1/539 | 0/536 | 0/541 | 0/541 |
| ConcussionInjury, poisoning and procedural complications | 1/539 | 0/536 | 0/541 | 0/541 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/539 | 0/536 | 0/541 | 0/541 |
| Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/539 | 0/536 | 0/541 | 0/541 |
| Event | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 |
|---|---|---|---|---|
| Injection site painGeneral disorders | 393/539 | 391/536 | 400/541 | 328/541 |
| FatigueGeneral disorders | 206/539 | 184/536 | 187/541 | 184/541 |
| HeadacheNervous system disorders | 165/539 | 154/536 | 154/541 | 131/541 |
| MyalgiaMusculoskeletal and connective tissue disorders | 98/539 | 75/536 | 95/541 | 49/541 |
| Injection site swellingGeneral disorders | 68/539 | 82/536 | 64/541 | 41/541 |
| Injection site erythemaGeneral disorders | 74/539 | 79/536 | 71/541 | 41/541 |
| Age, Continuous(Years) | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 | Total |
|---|---|---|---|---|---|
| Mean | 34.8 ± 9.3 | 34.8 ± 9.2 | 34.3 ± 9.3 | 34.4 ± 9.2 | 34.6 ± 9.3 |
| Sex: Female, Male(Participants) | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 | Total |
|---|---|---|---|---|---|
| Female | 305 | 321 | 311 | 310 | 1247 |
| Male | 236 | 219 | 230 | 230 | 915 |
| Ethnicity (NIH/OMB)(Participants) | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 98 | 104 | 113 | 107 | 422 |
| Not Hispanic or Latino | 440 | 434 | 420 | 430 | 1724 |
| Unknown or Not Reported | 3 | 2 | 8 | 3 | 16 |
| Race (NIH/OMB)(Participants) | V116 Lot 1 | V116 Lot 2 | V116 Lot 3 | PPSV23 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 6 | 2 | 4 | 4 | 16 |
| Asian | 9 | 12 | 6 | 8 | 35 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 0 | 1 | 4 |
| Black or African American | 49 | 43 | 55 | 48 | 195 |
| White | 458 | 458 | 458 | 453 | 1827 |
| More than one race | 16 | 24 | 16 | 26 | 82 |
| Unknown or Not Reported | 1 | 0 | 2 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2022 to primary completion in May 2023, 9 months.
Results were first posted in May 2024, 11 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 9 months is below that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine